Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression (MISO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03062150 |
|
Recruitment Status :
Completed
First Posted : February 23, 2017
Last Update Posted : June 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The steroid hormone cortisol is released in response to stress and acts in the central nervous system upon glucocorticoid (GR) and mineralocorticoid receptors (MR). GR are widely distributed across the brain while MR are predominantly expressed in the hippocampus and prefrontal cortex - two brain areas closely related to memory and executive function. Stimulation of MR leads to an increase of glutamate that act on glutamatergic NMDA receptors in the hippocampus and prefrontal cortex. In previous studies, the investigators have shown that fludrocortisone, a mineralocorticoid receptor (MR) agonist, improves memory and executive function in depressed patients and healthy controls. However, depressed patients not only exhibit cognitive deficits in traditional neuropsychological domains such as memory or executive function. In addition, there are depression-specific alterations such as cognitive bias and deficits in social cognition, two clinically highly relevant areas. Therefore, the specific aims of this renewal proposal are two-fold:
- To examine whether beneficial effects of fludrocortisone in depressed patients can be extended to depression-specific cognitive bias and to social cognition
- To determine whether beneficial effects of fludrocortisone depend on NMDA-receptor function and whether these beneficial effects can be enhanced by NMDA receptor stimulation.
The investigators hypothesize that fludrocortisone will improve cognitive bias and social cognition in depressed patients and that its beneficial effects depend on the NMDA receptor. Therefore, the investigators further hypothesize that the effects of fludrocortisone can be enhanced by co-administration of the partial NMDA receptor agonist D-cycloserine.
The study not only advances current knowledge by further examining the mechanism of action by which MR stimulation exerts beneficial effects on cognition but extends these effects to depression-specific cognitive bias and alterations in social cognition. Furthermore, a potential interaction between MR and NMDA receptors is highly clinically relevant given the promising results with NMDA receptor antagonists in the treatment of major depression.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Major Depression | Drug: Placebo Drug: Fludrocortisone Drug: D-Cycloserine | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 232 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | randomized double-blind placebo-controlled parallel group design |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Basic Science |
| Official Title: | Effects of Mineralocorticoid Receptor Stimulation on Cognitive Bias and Social Cognition in Patients With Major Depression and Healthy Controls: What's the Role of NMDA Receptors? |
| Actual Study Start Date : | September 27, 2016 |
| Actual Primary Completion Date : | February 11, 2019 |
| Actual Study Completion Date : | February 11, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo+Placebo
Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
|
Drug: Placebo
Placebo |
|
Active Comparator: Fludrocortisone+Placebo
Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH. |
Drug: Placebo
Placebo Drug: Fludrocortisone Fludrocortisone |
|
Active Comparator: Placebo+D-Cycloserine
Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH. D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd |
Drug: Placebo
Placebo Drug: D-Cycloserine D-Cycloserine |
|
Active Comparator: Fludrocortison+D-Cycloserine
Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd |
Drug: Fludrocortisone
Fludrocortisone Drug: D-Cycloserine D-Cycloserine |
- Emotional dot probe [ Time Frame: 1 hour ]
In this task, two stimuli (each a photography of a face) are presented quickly on a computer screen (500 ms), and one face stimulus is replaced by a probe (1100 ms). Face pictures can show a sad, happy or neutral expression and are paired as neutralneutral, neutral-sad, or neutral-happy. Participants respond as fast as possible by pressing a key to correspond to the location of the probe.
Attentional bias can be derived by the average reaction time when the probe replaces negative stimuli (sad faces), the average reaction time when the probe replaces neutral stimuli (neutral faces), and the average reaction time of positive (happy faces) and neutral stimuli (neutral faces).
- Facial recognition task [ Time Frame: 1 hour ]
This emotion recognition task features two basic emotions - sadness and anger - and a number of control trials containing neutral face expressions. Overall, 6 male and 6 female faces were taken from the NIMSTIM scale (Tottenham et al. (2009); http://www.macbrain.org/resources.htm).
Two graduations from the full emotion (100%) were created (40% and 80%) and are presented in 24 trials per percentile rank in shades of grey. In addition, 24 control Trials are presented with 0% (neutral) emotion. Overall, the task contains 120 trials in randomized order. Each face is shown for 1 second and is replaced by a grey screen, which requests an answer by showing the three possible answers (sadness, anger, neutral). This screen is presented for 4 seconds and participants make their Responses by pressing one of three keys on the keyboard (arrow keys). Reaction time and correct responses are measured.
- Multifaceted Empathy Test (MET) [ Time Frame: 1 hour ]To assess cognitive and emotional empathy, the MET will be used (Dziobek et al , 2008) in a modified version (Hurlemann et al , 2007; Dziobek et al , 2011; Ritter et al , 2011). The MET is a PC-assisted test consisting of photographs that show 30 picture Stimuli with people in emotionally charged situations. To assess cognitive empathy, participants will be required to infer the mental state of the subject in the photo and will be asked to indicate the correct one from a list of four. To assess emotional empathy, participants will be asked to rate the degree of empathic concern they feel for the person in the Picture (Likert scale, 1 = not at all, 9 = very much).
- Virtual Water Maze [ Time Frame: 1 hour ]
Participants are placed in a virtual reality, presented on a computer screen, consisting of a room with a pool in the center. In the pool, there is an invisible platform, that participants have to reach as fast as possible. Participants can move in an ego-perspective with a joystick. In several trials, participants learn to reach the platform. The better participants learn, the faster they reach the platform and the shorter is the path they used.
In the last trial, participants do not get to know whether they reached the platform. The time (sec) spent in the right quadrant, is the outcome measurement, used to determine visuospatial memory.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 18-65 years
- Depressed male and female patients according to DSM-V & minimum of 17-items Hamilton Depression Score of 18
- healthy controls
- informed consent signed
Exclusion Criteria:
- Current use of antidepressants, antipsychotics, or mood stabilizer
- Relevant medical or neurological disorders
- Pregnancy or unsure contraception
- Relevant psychiatric comorbidity (bipolar or psychotic disorders)
- Active alcohol or other substance abuse/dependance
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03062150
| Germany | |
| Charité Universitätsmedizin Berlin | |
| Berlin, Germany, 12203 | |
| Principal Investigator: | Christian Otte, MD | Charité University Medical Center Berlin, Dept. of Psychiatry |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Prof. Dr. Christian Otte, Professor of Psychiatry, Charite University, Berlin, Germany |
| ClinicalTrials.gov Identifier: | NCT03062150 |
| Other Study ID Numbers: |
OT 209/7-1 2014-005239-15 ( EudraCT Number ) |
| First Posted: | February 23, 2017 Key Record Dates |
| Last Update Posted: | June 23, 2020 |
| Last Verified: | June 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Depression Depressive Disorder Depressive Disorder, Major Behavioral Symptoms Mood Disorders Mental Disorders Cycloserine Fludrocortisone Anti-Infective Agents, Urinary |
Anti-Infective Agents Renal Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Anti-Inflammatory Agents |